#28Growth Hormone & Body Composition
CJC-1295 without DAC
GHRH analogue listing without drug-affinity-complex modification
Evidence: other human studyReviewed 2026-07-25
Investigated uses
- No adequately documented human investigated use for the exact catalog identity/formulation was identified; any vendor-promoted goals were excluded from evidence grading.
Mechanism and hypotheses
- A no-DAC GHRH-analogue listing is intended to stimulate pituitary growth-hormone release, but commercial identity is often conflated with modified GRF(1-29).
- Hypothesized: Efficacy and safety cannot be transferred from DAC-conjugated CJC-1295 without identity and pharmacokinetic confirmation.
Human evidence
- Human evidence directly matching the commercial “no DAC” identity was not adequately resolved; much cited evidence concerns DAC-conjugated CJC-1295. Limitations: Identity and pharmacokinetic mismatch.
Safety highlights
- Unknown or insufficiently characterized for the exact catalog product.
- Identity, purity, sterility, endotoxin, aggregation, immunogenicity, concentration and route-specific risks are not adequately characterized.
Regulatory context
No FDA-approved CJC-1295 no-DAC product was identified; FDA lists CJC-1295 among substances presenting significant compounding safety concerns.
Sources used for this entry
- PubMed search: CJC-1295 without DAC — PubMed
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks — U.S. Food and Drug Administration
- Drugs@FDA database — U.S. Food and Drug Administration
- EMA medicines search — European Medicines Agency
- NCT00267527: CJC-1295 in HIV-associated visceral adiposity — ClinicalTrials.gov
- Prolonged stimulation of growth hormone and IGF-I by CJC-1295 — Journal of Clinical Endocrinology & Metabolism / PubMed